Contributors: Global CF Registry Collaboration; Kasmi, I.; Drali, O.; Burghart, S.; Lakatos-Krepcik, A.; Eder, J.; Jaksch, P.; Kainz, K.; Kallinger, M.; Leitner, A.; Mozdzen, M.; Pfleger, A.; Renner, S.; Stadlinger, M.; Thir, C.; Nuriyev, E.; Boboli, H.; De Wachter, E.; Dupont, L.; Gohy, S.; Hanssens, L.; Knoop, C.; Lammertyn, E.; Nowé, V.; Pirson, J.; Thimmesch, M.; Van Braeckel, E.; Van Hoorenbeeck, K.; Vanderhelst, E.; Filho, E.P.; Athanazio, R.A.; Martins, V.C.; Duarte, M.C.; Monte, LFV; de Fuccio, M.B.; Knabben, ASC; Melloti, R.; Meneses, D.G.; Petrova, G.; Tješić-Drinković, D.; Dugac, A.V.; Bambir, I.; Yiallouros, P.; Bilkova, A.; Drevinek, P.; Macek, M.; Olesen, H.V.; Pressler, T.; Fouda, E.M.; Nasr, S.; Weldetsadik, A.Y.; Al-Iede, M.; Abdrakhmanov, O.; Corvol, H.; Lemonnier-Videau, L.; Abely, M.; Piccini, C.B.; Belleguic, C.; Bihouee, T.; Billon, Y.; Bui, S.; Camara, B.; Cheraud, M.C.; Chiron, R.; Duet, E.C.; Cosson, L.; Dalphin, M.L.; Boucher, I.D.; De Miranda, S.; Deneuville, E.; Dubus, J.C.; Durieu, I.; Epaud, R.; Gerardin, M.; Grenet, D.; Houdouin, V.; Huet, F.; Reem, K.; Kessler, R.; Languepin, J.; Laurans, M.; Leroy, S.; Llerena, C.; Macey, J.; Mankikian, J.; Marguet, C.; Martin, C.; Mely, L.; Mittaine, M.; Murris-Espin, M.; Perisson, C.; Prevotat, A.; Ramel, S.; Rames, C.; Reix, P.; Revillon, M.; Reynaud-Gaubert, M.; Richaud-Thiriez, B.; Rittie, J.L.; Scalbert-Dujardin, M.
نبذة مختصرة : Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact of COVID-19 infection on the trajectory of lung function and nutritional status in people with cystic fibrosis (pwCF). This is a retrospective global cohort study of pwCF who had confirmed COVID-19 infection diagnosed between January 1, 2020 and December 31, 2021. Forced expiratory volume in one second percent predicted (ppFEV 1 ) and body mass index (BMI) twelve months prior to and following a diagnosis of COVID-19 were recorded. Change in mean ppFEV 1 and BMI were compared using a t-test. A linear mixed-effects model was used to estimate change over time and to compare the rate of change before and after infection. A total of 6,500 cases of COVID-19 in pwCF from 33 countries were included for analysis. The mean difference in ppFEV 1 pre- and post-infection was 1.4 %, (95 % CI 1.1, 1.7). In those not on modulators, the difference in rate of change pre- and post-infection was 1.34 %, (95 % CI -0.88, 3.56) per year (p = 0.24) and -0.74 % (-1.89, 0.41) per year (p = 0.21) for those on elexacaftor/tezacaftor/ivacaftor. No clinically significant change was noted in BMI or BMI percentile before and after COVID-19 infection. No clinically meaningful impact on lung function and BMI trajectory in the year following infection with COVID-19 was identified. This work highlights the ability of the global CF community to unify and address critical issues facing pwCF.
Processing Request
No Comments.